Actemra (tocilizumab) was recently approved by Health Canada to treat children with polyarticular-course juvenile idiopathic arthritis (polyJIA), a rare, chronic and debilitating form of childhood arthritis. The medicine can be used for the treatment of signs and symptoms of active polyarticular juvenile idiopathic arthritis in patients two years of age and older who have not responded adequately to previous therapy with disease modifying anti-rheumatic drugs (DMARDs) and systemic corticosteroids. Actemra can be used alone (in cases of intolerance to methotrexate or where treatment with methotrexate is not appropriate) or in combination with methotrexate.  For more details, go to: http://www.newswire.ca/en/story/1245507/health-canada-approves-treatment-for-children-with-rare-form...